Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
Get Alerts AEGR Hot Sheet
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Leerink Partners maintained an Outperform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $6.00 (from $15.00), following the company's 1Q earnings report. AEGR reported revenue of $36M, missing consensus estimates of $43M. Management cut FY16 guidance at the midpoint from $160-190M to $130-150M.
Analyst Joseph Schwartz commented, "Based on low Juxtapid revenue in 1Q ($36M in line w/ last week's preannouncement vs our/ consensus $44M/$43M) leading to a top- & bottom-line miss and indications of weakness going forward, mgmt. revised downward FY16 guidance by 20% at the midpoint from $160-190M to $130-150M. As a reminder, top-line FY16 guidance previously disappointed investors in January when it came in meaningfully below consensus. We are updating our model to reflect these financial results and lowering our PT to $6."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $2.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MarineMax (HZO) PT Lowered to $35 at Stifel
- World Kinect Corporation (WKC) Misses Q1 EPS by 2c, Misses on Revenue
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!